Skip to main
  1. Stocks
  2. Disc Medicine Inc
  3. Forecast
IRON

IRON Stock Forecast & Price Target

IRON Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Disc Medicine is supported by a de-risked, mechanism-driven pipeline that targets major unmet needs in hematologic disease, with bitopertin now showing decisive Phase 3 evidence in EPP/XLP and supporting a path to approval and launch. Its MF-anemia program, selcodebart, has shown a 50% to 64% major hematologic response in interim Phase 2 data where no approved therapy exists, while DISC-3405 adds another differentiated shot on goal in PV with convenient dosing and a potentially meaningful commercial niche. Financially, the company reported a $1.53 loss per share for 3Q, R&D of $44.1M, operating loss of $64.2M, and cash, cash equivalents, and marketable securities of $682.8M, with a public offering adding roughly $485.9M in net proceeds to support operations into 2030.

Bears say

Disc Medicine is exposed to the classic biotech risks of clinical, regulatory, financing, manufacturing, and IP setbacks, but the more important issue is pipeline fragility: bitopertin could face additional NDA delays and, even if approved, may see slower-than-expected uptake in a largely treatment-naïve EPP/XLP population. The bearish case is amplified by selcodebart, where unforeseen safety problems or efficacy falling below a 30% responder rate in MF-anemia would leave it only minimally differentiated versus current options and potentially limit share to about 10% of anemic patients. Competition in PV also looks unfavorable, as better-than-expected Ph 3 results from divesiran or sapablursen could pressure Disc Medicine’s commercial prospects while physicians remain cautious about anemia risk from extended dosing.

IRON has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

IRON Analyst Forecast & Price Prediction

Get the latest IRON stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in IRON

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Disc Medicine Inc (IRON) Forecast

Analysts have given IRON a Buy based on their latest research and market trends.

According to 9 analysts, IRON has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $123.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $123.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Disc Medicine Inc (IRON)


IRON Analyst Forecast & Price Prediction

Get the latest IRON stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in IRON

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover IRON stock data and trends